Daré Bioscience Advances Women's Health Strategy with New Product Launch and HPV Clinical Study

Daré Bioscience reported its second-quarter 2026 results, highlighting the commercial launch of Flora Sync LF5™, its first directly commercialized product, which began generating revenue in July. The company is also progressing with DARE to PLAY™ Sildenafil Cream and has initiated a Phase 2 study for DARE-HPV, an investigational therapeutic for high-risk HPV infection, with funding from the National Institute of Allergy and Infectious Disease (NIAID).